Literature DB >> 21253121

Allogeneic and autologous bone-marrow transplantation.

H J Deeg.   

Abstract

The author of this paper presents an overview of the current status of bone marrow transplantation, including indications, pre-transplant considerations, the transplant procedure, acute and delayed transplant-related problems, results currently attainable, and a short discussion of possible future developments.

Year:  1988        PMID： 21253121      PMCID： PMC2218992     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


  59 in total

1.  Marrow transplantation for the treatment of chronic myelogenous leukemia.

Authors:  E D Thomas; R A Clift; A Fefer; F R Appelbaum; P Beatty; W I Bensinger; C D Buckner; M A Cheever; H J Deeg; K Doney
Journal:  Ann Intern Med       Date:  1986-02       Impact factor: 25.391

2.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

Authors:  J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

3.  Government regulations and sickle cell trait.

Authors:  B F Cameron; D B Smith; B Cody
Journal:  Blood       Date:  1983-06       Impact factor: 22.113

4.  Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.

Authors:  K M Sullivan; R P Witherspoon; R Storb; H J Deeg; S Dahlberg; J E Sanders; F R Appelbaum; K C Doney; P Weiden; C Anasetti
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

5.  Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation.

Authors:  J E Sanders; C D Buckner; J M Leonard; K M Sullivan; R P Witherspoon; H J Deeg; R Storb; E D Thomas
Journal:  Transplantation       Date:  1983-09       Impact factor: 4.939

6.  Allogeneic bone marrow transplantation as treatment for accelerating chronic myelogenous leukemia.

Authors:  P B McGlave; D C Arthur; D Weisdorf; T Kim; A Goldman; D D Hurd; N K Ramsay; J H Kersey
Journal:  Blood       Date:  1984-01       Impact factor: 22.113

7.  Allogeneic marrow grafting with partially mismatched, unrelated marrow donors.

Authors:  R D Gingrich; G D Ginder; N E Goeken; C W Howe; B C Wen; D H Hussey; M A Fyfe
Journal:  Blood       Date:  1988-05       Impact factor: 22.113

8.  Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.

Authors:  K M Sullivan; H M Shulman; R Storb; P L Weiden; R P Witherspoon; G B McDonald; M M Schubert; K Atkinson; E D Thomas
Journal:  Blood       Date:  1981-02       Impact factor: 22.113

9.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

Authors:  T Philip; J O Armitage; G Spitzer; F Chauvin; S Jagannath; J Y Cahn; P Colombat; A H Goldstone; N C Gorin; M Flesh
Journal:  N Engl J Med       Date:  1987-06-11       Impact factor: 91.245

10.  Transplantation of marrow from an unrelated donor to a patient with acute leukemia.

Authors:  J A Hansen; R A Clift; E D Thomas; C D Buckner; R Storb; E R Giblett
Journal:  N Engl J Med       Date:  1980-09-04       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.